Below are current clinical trials.5 studies in Nonalcoholic fatty liver disease
(open studies only).
Filter this list of studies by location, status and more.
A variety of liver insults lead to pathological changes in liver architecture that culminate in cirrhosis. While invasive liver biopsy was required to detect cirrhosis, the development of magnetic resonance elastography (MRE) has revolutionized our ability to detect liver fibrosis through non-invasive means that involve measurement of liver stiffness. However, a number of pathological findings occur in liver in response to various insults that precede cirrhosis and are clinically important to identify such as steatosis associated with NASH, inflammation associated with viral hepatitis, and congestion associated with cardiac hepatopathy. Detection of such entities provides essential diagnostic, prognostic, and treatment information but yet is not available non-invasively. Recent murine studies from this group of investigators has identified that MRE technology can be adapted to non-invasively detect these conditions. Implementing this into the practice will transform it by obviating the need for invasive liver biopsies in patients suspected of having such forms of suspected liver disease. This will differentiate Mayo from other institutions where such technology is not available.
An additional aim of this study is to examine the impact of obstructive sleep apnea (OSA) on the pathogenesis of nonalcoholic fatty liver disease (NAFLD), both common comorbidities of obesity. Recent evidence indicates a potential link between OSA and severity of NASH and fibrosis, but the mechanisms of OSA- associated hypoxia on liver disease progression in NAFLD is unclear. This study offers the unique opportunity to analyze this association, as the study population will undergo routine evaluation for OSA, as part as the preoperative work-up prior to bariatric surgery.
The primary objectives of this study are to evaluate the safety and effectiveness of obeticholic acid treatment compared to placebo in patients with non-cirrhotic, nonalcoholic steatohepatitis (NASH) with liver fibrosis.
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFL or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients with NAFL or NASH within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
The goal of this study is to examine the current and (potential) future therapeutic relevance of PGx testing in established patients with liver disease seen in the Division of Gastroenterology/Hepatology, in order to improve patient clinical care at Mayo Clinic with more effective and efficient prescribing of medications.
Rochester, Minn., La Crosse, Wis.
The purpose of this study is to assess a new drug to decrease liver fat in subjects with Non-Alcoholic Steatohepatitis or Non-Alcoholic Fatty Liver Disease.
Aug. 11, 2017
- Chalasani N, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases and American College of Gastroenterology. Gastroenterology. 2012;142:1592.
- Feldman M, et al. Nonalcoholic fatty liver disease. In: Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 10th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. http://www.clinicalkey.com. Accessed May 10, 2016.
- Rinella M. Nonalcoholic fatty liver disease: A systematic review. Journal of the American Medical Association. 2015;313:2263. http://jama.jamanetwork.com/ Accessed May 10, 2016.
- Spengler E, et al. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. http://www.mayoclinicproceedings.org/article/S0025-6196(15)00510-8/abstract. Mayo Clinic Proceedings. 2015;90:1233. Accessed May 10, 2015.
- Barbara Woodward Lips Patient Education Center. Nonalcoholic fatty liver disease. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2009.
- Venkatesh SK, et al. Magnetic resonance elastography of liver: Technique, analysis and clinical applications. Journal of Magnetic Resonance Imaging. 2013;37:544.
- Kim D, et al. Advanced fibrosis in nonalcoholic fatty liver disease: Noninvasive assessment with MR elastography. Radiology. 2013;268:411.
- Sheth SG, et al. Nonalcoholic fatty liver disease: Natural history and management. http://www.uptodate.com/home. Accessed May 10, 2016.
- Boyer TD, et al. Nonalcoholic fatty liver disease. In: Zakim & Boyer's Hepatology: A Textbook of Liver Disease. 6th ed. Philadelphia, Pa: Saunders Elsevier, 2012. http://www.clinicalkey.com. Accessed May 10, 2015.
- Molloy JW, et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis and degree of hepatic fibrosis. Hepatology. 2012;55:429.
- Malhi H, et al. Nonalcoholic fatty liver: Optimizing pretransplant selection and posttransplant care to maximize survival. Current Opinion in Organ Transplantation. 2016, 21:99.
- Heimbach J, et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. American Journal of Transplantation. 2013; 13:363.
- Watt KD (expert opinion). Mayo Clinic, Rochester, Minn. Personal communication. July 7, 2016.
- Ludwig J, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings. 1980;55:434.
- Uppal V, et al. Pediatric non-alcoholic fatty liver disease. Current Gastroenterology Reports. 2016;18:24.
Nonalcoholic fatty liver disease